Cordis' CypherSelect Plus stent approved in Europe

By Elaine Rigoli

Tampa, Fla., June 22 - Cordis Corp. said its CypherSelect Plus has become the first third-generation drug-eluting stent to receive CE Mark approval and will be sold in Europe in September with full market launch by the end of the year.

With CE mark now secured, the company said it is aggressively building its manufacturing capacity for the CypherSelect Plus launch to provide ready access to physicians as it becomes available in various countries outside the United States.

In 2004, Cordis introduced the first second-generation drug-eluting stent - CypherSelect - outside the United States.

Cordis, a Johnson & Johnson company, develops interventional vascular technology products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.